Immunotherapy of cancer using dendritic cells

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 1, 1998, Pages 35-44

  Morse, Michael A ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Active immunotherapy; Dendritic cells; Tumor antigens

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DENDRITIC CELL; FEASIBILITY STUDY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031950192     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Robinson MR, Rigby CC, Pugh CB et al, Adjuvant immunotherapy with BCG in carcinoma of the prostate. Dr J Urol (1977) 49: 221-6.
2. Bulbul MA, Huben RP, Murpy GP, Interferon-β treatment of metastatic prostate cancer. J Surg Oncol (1989) 33: 231-3.
3. Rosenberg SA, Lotze MT, Yang JC et al, Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer. Ann Surg (1989) 210: 474-85.
4. Rosenberg SA, Lotze MT, Muul LM et al, A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 316: 889-97.
5. Topalian SL, Solomon D, Avid FP et al, Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2, a pilot study. J Clin Oncol (1988) 6: 839-53.
6. Darrow T, Slingluff C, Seigler H, The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol (1989) 42: 3329-35.
7. Halbert C, Demers GW, Galloway DA, The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 65: 473-8.
8. Bos JL, ras oncogenes in human cancer: a review. Cancer Res (1989) 49: 4682-9.
9. Thompson JA, Grunert F, Zimmermann W, Carcinoembryonic antigen gene family: molecular biology and clinical prospectives. J Clin Lab Anal (1991) 5: 344-66.
10. Van der Bruggen PC, Traversari C, Chomez P et al, A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science (1991) 254: 1643-7.
11. Disis ML, Cheever MA, HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res (1997) 71: 343-71.
12. Kawakami Y, Eliyahu S, Delgado CH et al, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA (1994) 91: 3515-19.
13. Barnd DL, Lan MS, Metzgar RS, Finn OJ, Specific MHC-unrestricted recognition of tumor associated mucins by human cytotoxic cells. Proc Natl Acad Sci USA (1989) 86: 7159-63.
14. Van Den Eynde B, Hainut P, Herin M et al, Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 44: 634-40.
15. Coulie PG, Somville M, Lehmann F et al, Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells Int J Cancer (1992) 50: 289-97.
16. Mazzocchi A, Belli F, Mascheroni L et al, Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor invaded lymph nodes of melanoma patients. Int J Cancer (1994) 58: 330-9.
17. van Pel A, Boon T, Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA (1982) 79: 4718-22.
18. Dranoff G, Jaffee E, Lazenby A et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90: 3539-43.
19. Townsend SE, Allison JP, Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259: 368-70.
20. Gilboa E, Lyerly HK, Specific active immunotherapy of cancer using genetically modified tumor vaccines. Biol Ther Cancer Updates (1994) 4: 1-16.
21. McAneny D, Ryan CA, Beazley RM, Kaufman HL, Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol (1996) 3: 495-500.
22. Tsang KY, Zaremba S, Nieroda CA et al, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 87: 982-90.
23. Conry RM, LoBuglio AF, Moore SE et al, A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther (1995) 2: 59-65.
24. Huang AYC, Golumbek P, Ahmadzedah M et al, Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264: 961-5.
25. Tazi A, Bouchonnet F, Gransaigne M et al, Evidence that granulocyte-macrophage-colony stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest (1993) 91: 566-76.
26. Becker Y, Dendritic cell activity against primary tumors: an overview. In Vivo (1993) 7: 187-91.
27. Becker Y, Anticancer role of dendritic cells (DC) in human and experimental cancers - a review. Anticancer Res (1992) 12: 511-20.
28. Azizi E, Bunana C, Goldberg L, Kripke ML, Perturbations of epidermal Langerhans cells in basal cell carcinoma. Am J Dermatopath (1987) 9: 465-73.
29. Steinman RM, The dendritic cell system and its role in immunogenicity. Ann Rev Immunol (1991) 9: 271-96.
30. Inaba K, Young JW, Steinman RM, Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J Exp Med (1987) 166: 182-94.
31. Young JW, Steinman RM, Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med (1990) 171: 1315-32.
32. Katz SI, Tamaki K, Sachs DH, Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature (1979) 282: 324-6.
33. Frelinger JG, Hood L, Hill S, Frelinger JA, Mouse epidermal Ia molecules have a bone marrow origin. Nature (1979) 282: 321-3.
34. Szabolcs P, Moore MAS, Young JW, Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol (1995) 154: 5851-61.
35. Santiago-Schwarz F, Belilos E, Diamond B et al, TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leuk Biol (1992) 52: 274-81.
36. Inaba K, Inaba M, Deguchi K et al, Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci USA (1993) 90: 3038-42.
37. Caux C, Vandervliet B, Massacrier C et al, CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNFα. J Exp Med (1996) 184: 695-706.
38. Szabolcs P, Avigan D, Gezelter S et al, Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony forming unit intermediate. Blood (1996) 87: 4520-30.
39. Zhou L-J, Tedder TF, CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA (1996) 93: 2588-92.
40. Heufler C, Koch F, Schuler G, Granulocyte/macrophage colony-stimulating factor and interleukin-1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med (1988) 167: 700-5.
41. Saunders D, Lucas K, Ismaili J et al, Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte-macrophage colony stimulating factor. J Exp Med (1996) 184: 2185-96.
42. Galy A, Travis M, Cen D, Chen B, Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity (1993) 3: 459-73.
43. Wu L, Antica M, Johnson GR et al, Developmental potential of earliest precursor cells from adult thymus. J Exp Med (1991) 174: 1617-27.
44. Suss G, Shortman K, A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med (1996) 183: 1789-96.
45. Grouard G, Rissoan MC, Filguiera L et al, The enigmatic plasma-cytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med (1997) 185: 1101-11.
46. Liu YJ, Grouard G, de Boutteillier O, Banchereau J, Follicular dendritic cells and germinal centers. Int Rev Cytol (1996) 166: 139-79.
47. Grouard G, Durand I, Filgueira L et al, Dendritic cells capable of stimulating T cells in germinal centers. Nature (1996) 384: 364-7
48. Zhou L-J, Tedder TP, Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol (1995) 154: 3821-35.
49. Hock BD, Starling GC, Daniel PB, Hart DNJ, CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunol (1994) 83: 573-81.
50. Austyn JM, Antigen uptake and presentation by dendritic leukocytes. Semin Immunol (1992) 4: 227-36.
51. Sallusto F, Lanzavecchia A, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med (1994) 179: 1109-18.
52. Caux C, Massacrier C, Vanbervliet B et al, Activation of human dendritic cells through CD40 cross-linking. J Exp Med (1994) 180: 1263-72.
53. Macatonia SE, Knight SC, Edwards AJ et al, Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. J Exp Med (1987) 166: 1654-67.
54. Crowley M, Inaba K, Steinman RM, Dendritic cells are the principal cell in mouse spleen bearing immunogenic fragments of foreign proteins. J Exp Med (1990) 172: 383-6.
55. Levine TP, Chain BM, Endocytosis by antigen presenting cells: dendritic cells are as endocytically active as other antigen presenting cells. Proc Natl Acad Sci USA (1992) 89: 8342-6.
56. Sallusto F, Cella M, Danieli C, Lanzavecchia A, Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex II compartment: downregulation by cytokines and bacterial products. J Exp Med (1995) 182: 389-400.
57. Reis e Sousa C, Stahl PD, Austin JM, Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med (1993) 178: 509-19.
58. Scheicher C, Mehlig M, Dienes H-P, Reske K, Uptake of microparticle-absorbed protein antigen by bone marrow derived dendritic cells results in upregulation of interleukin 1a and interleukin 12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol (1995) 25: 1566-77.
59. Guery J-C, Adorini, Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol (1995) 154: 536-44.
60. Lehner PJ, Cresswell P, Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol (1996) 8: 59-67.
61. Celluzzi CM, Mayordomo JI, Storkus WJ et al, Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med (1996) 183: 283-7.
62. Ruff AL, Guarnieri FG, Staveley-O'Carroll K et al, The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem (1997) 272: 8671-8.
63. McKinney EC, Streilein EW, On the extraordinary capacity of allogeneic epidermal Langerhans cells to prime cytotoxic T cells in vivo. J Immunol (1989) 143: 1560-4.
64. Macatonia SE, Taylor PM, Knight SC, Askonas BA, Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med (1988) 169: 1255-64.
65. Nair S, Zhou F, Reddy R et al, Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med (1992) 175: 609-12.
66. Mehta-Damani A, Markowicz S, Engleman EG, Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol (1994) 153: 996-1003.
67. Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky JA, Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol (1993) 5: 849-57.
68. Nair S, Babu JS, Dunham RG et al, Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J Virol (1993) 67: 4062-9.
69. Rouse RJD, Nair SK, Lydy SL et al, Induction in vitro of primary cytotoxic T-lymphocytes responses with DNA encoding herpes simplex virus proteins. J Virol (1994) 68: 5685-9.
70. Flamand V, Sornasse T, Thielemans K et al, Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo Eur J Immunol (1994) 24: 605-10.
71. Paglia P, Chiodoni C, Rodolfo M, Colombo MP, Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med (1996) 183: 317-22.
72. Porgador A, Snyder D, Gilboa E, Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol (1996) 156: 2918-26.
73. Porgador A, Gilboa E, Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med (1995) 182: 255-60.
74. Ossevoort MA, Feltkamp MCW, van Veen KJH et al, Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother (1995) 18: 86-94.
75. Mayordomo JI, Zorina T, Storkus WJ et al, Bone marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med (1995) 12: 1297-302.
76. Reid CDL, Fryer PR, Clifford C et al, Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood (1990) 76: 1139-49.
77. Egner W, Andreesen R, Hart D, Allostimulatory cells in fresh human blood. Transplantation (1993) 56: 945-50.
78. Nestle F, Zheng X, Thompson C et al, Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunother (1993) 151: 6535-45.
79. Young J, Steinman R, Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells Cell Immunol (1988) 111: 167-82.
80. Knight SC, Farrant J, Bryant A et al, Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology. Immunol (1986) 57: 595-603.
81. Williams LA, Egner W, Hart DNJ, Isolation and function of human dendritic cells. Int Rev Cytol (1994) 153: 41-103.
82. Thomas R, Davis L, Lipsky P, Isolation and characterization of human peripheral blood dendritic cells. J Immunol (1993) 150: 821-34.
83. Van Voorhis W, Hair L, Steinman R et al, Human dendritic cells: enrichment and characterization from peripheral blood. J Exp Med (1982) 155: 1172-87.
84. Gabrilovich DI, Ciernik IF, Carbone DP, Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol (1996) 170: 101-10.
85. Gabrilovich DI, Nadaf S, Corak J et al, Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor bearing mice, are effective antigen earners in the therapy of established tumors. Cell Immunol (1996) 170: 111-19.
86. Gabrilovich DI, Chen HL, Girgis K et al, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med (1996) 10: 1096-103.
87. Reid CDL, Stackpoole A, Meager A et al, Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol (1992) 149: 2681-8.
88. Inaba K, Inaba M, Romani N et al, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte macrophage colony-stimulating factor. J Exp Med (1992) 176: 1693-702.
89. Santiago-Schwarz F, Divaris N, Kay C et al, Mechanisms of tumor necrosis factor-α and granulocyte-macrophage colony-stimulating factor-induced dendritic cell development Blood (1993) 82: 3019-28.
90. Romani N, Gruner S, Brang D et al, Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 180: 83-93.
91. Caux C, Dezutter-Dambuyant C, Schmitt D et al, GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature (1992) 360: 258-61
92. Siena S, Di Nicola M, Bregni M et al, Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anti-cancer therapy. Exp Hematol (1995) 23: 1463-71.
93. Bender A, Sapp M, Schuler G et al, Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Meth (1996) 196: 121-35.
94. Romani N, Reider D, Heuer M et al, Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Meth (1996) 196: 137-51.
95. Morse MA, Zhou L-J, Tedder TF et al, Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNF-α for use in cancer immunotherapy. Ann Surg (1997) 226: 6-16.
96. Wong C, Morse M, Nair SK, Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother (in press).
97. Alijagic S, Moller P, Artuc M et al, Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol (1995) 25: 3100-7.
98. Boczkowski D, Nair S, Snyder D, Gilboa E, Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo. J Exp Med (1996) 184: 465-72.
99. Nair SK, Snyder D, Rouse BT, Gilboa E, Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer (1997) 70: 706-15.
100. Gong J, Chen D, Kashiwaba M, Kufe D, Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med (1997) 3: 558-61.
101. Bhardwaj N, Bender A, Gonzalez N et al, Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J. Clin Invest (1994) 94: 797-807.
102. Greenberg PD, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 49: 281-355.
103. Harnaoka T, Fujiwara H, Phenotypically and functionally distinct T cell subsets in anti-tumor responses. Immunol Today (1987) 8: 267-9.
104. Zirvogel L, Mayordomo JI, Tjandrawan T et al, Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th1-associated cytokines. J Exp Med (1996) 183: 87-97.
105. Nair SK, Boczkowski D, Snyder D, Gilboa E, Antigen-presenting cells pulsed with unfracrionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol (1997) 27: 589-97.
106. Nair SK, Boczkowski D, Morse MA et al, Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Submitted to Nature Biotechnol.
107. Anichini A, Mortarini R, Maccalli C et al, Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol (1996) 156: 208-17.
108. Tsang KY, Zaremba S, Nieroda CA et al, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 87: 982-90
109. Mukherji B, Chakraborty NG, Yamasaki S et al, Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA (1995) 92: 8078-82.
110. Hsu FJ, Benike C, Fagnoni F et al, Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med (1996) 2: 52-8.
111. Reichardt V, Okada C, Benike C et al, Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood (1996) 88: 481 (abst).
112. Murphy G, Tjoa B, Ragde H et al, Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. The Prostate (1996) 29: 371-80.
113. Maraskovsky E, Brasel K, Teepe M et al, Dramatic increase in the number of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 184: 1953-62.